Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BUB1 | O43683 | 9/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | GUCY1A1 | Q02108 | 7/20 | 0.46 |
| ▸ | GUCY1B1 | Q02153 | 7/20 | 0.46 |
| ▸ | FABP3 | P05413 | 1/20 | 0.43 |
| ▸ | PDE5A | O76074 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23161926 | 1.00 | BUB1 (0.51) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23162008 | 0.92 | BUB1 (0.50) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL20534736 | 0.90 | BUB1 (0.50) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23161970 | 0.90 | ADORA3 (0.51) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23162032 | 0.89 | BUB1 (0.49) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL29637214 | 0.89 | BUB1 (0.49) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL29381976 | 0.88 | BUB1 (0.47) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23186753 | 0.88 | BUB1 (0.47) | BUB1ADORA3KCNH2GUCY1A1GUCY1B1 | |
| SCHEMBL23162030 | 0.88 | BUB1 (0.54) | BUB1ADORA3KCNH2PDE5A | |
| SCHEMBL29637223 | 0.88 | BUB1 (0.54) | BUB1ADORA3KCNH2PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3609883-B1 | FLUORINE-SUBSTITUTED INDAZOLE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2022-06-29 | — | — | EP | disclosed |